meta analysis? [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2010-08-06 20:31 (5403 d 20:51 ago) – Posting: # 5735
Views: 17,750

Dear ElMaestro!

❝ I am afraid I do not have a qualified opinion.


Me not either, but I’m a little bit concerned about the (lacking) α-spending in meta analysis.

❝ Do you have a good idea about m.a.? I'd be happy to hear.


See Chapter 16 in Chow & Liu (3rd ed. 2009). They refer to two models (based on 2×2 cross-over studies only), where the first one is rather restrictive – assuming equal CVintra and CVinter across studies. Personal experience: nil.


  1. Chow S-C, Liu J-p. Meta-analysis for bioequivalence review.
    J Biopharm Stat. 1997:7(1):97–111. doi:10.1080/10543409708835172
  2. Chow S-C, J Shao J. Bioequivalence review for drug interchangeability.
    J Biopharm Stat. 1999;9(3):485–97. doi:10.1081/BIP-100101189

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,681 registered users;
56 visitors (0 registered, 56 guests [including 36 identified bots]).
Forum time: 17:23 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5